Lung Therapeutics (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Lung Therapeutics

Pioneering safer pathways in lung disease treatment with pharmaceutical solutions.

Founded 2013 11-50 employees Series C Total: $53.91M Biotechnology, Health Care +1

Lung Therapeutics, founded in 2013, is a biotechnology and healthcare startup that is pioneering safer pathways in lung disease treatment with pharmaceutical solutions. The company's focus is on niche, orphan drug indications for lung injury and diseases, particularly fibrosis. Their primary current project involves addressing loculated pleural effusion, a severe complication of pneumonia where fluid accumulates in the chest cavity surrounding the lungs, and fibrinous scar tissue obstructs fluid drainage. Their initial product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is under study for the safe removal of fibrinous scar tissue in patients with loculated pleural effusion. This pharmaceutical intervention aims to significantly improve the clinical pathway for these patients, allowing for simple draining of pleural fluid without the need for surgery. In June 2019, the company received a $36.00M Series C investment from Bios Partners. The long-term focus of Lung Therapeutics' efforts will be on enhancing clinical pathways for Acute Lung Injury, Idiopathic Pulmonary Fibrosis, and other related disease conditions. Lung Therapeutics is a promising player in the biotechnology and healthcare industries, with a strong focus on addressing critical unmet medical needs within the field of lung diseases. The recent investment from Bios Partners underscores investor confidence in the potential of the company's pharmaceutical solutions for improving the treatment of lung-related conditions.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	••••••	1		04 Jun 2019
Series B	••••••	2		06 Jun 2017
Venture Round	••••••	-		07 Mar 2016
Series A	••••••	1		30 Sep 2015
Non Equity Assistance	••••••	1	•••• ••••	20 Dec 2013

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

••••••

04 Jun 2019

Series B

••••••

06 Jun 2017

Venture Round

••••••

07 Mar 2016

Series A

••••••

30 Sep 2015

Non Equity Assistance

••••••

•••• ••••

20 Dec 2013

FAQ About Lung Therapeutics

Pioneering safer pathways in lung disease treatment with pharmaceutical solutions.

Lung Therapeutics was founded in 2013.

Lung Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.

Lung Therapeutics has approximately 11-50 employees.

Lung Therapeutics has completed 6 funding rounds, raising a total of $53.91M. The latest funding stage is Series C.

Top alternatives and competitors to Lung Therapeutics include Aileron Therapeutics, Qureight, Avalyn Pharma, Chemomab Therapeutics, Alveolus Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Lung Therapeutics and Aileron Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Lung Therapeutics

General Information

Track Lung Therapeutics

Discover More

About Lung Therapeutics

Funding Rounds & Investors (6)

Lung Therapeutics Alternatives & Competitors

FAQ About Lung Therapeutics

Don't just browse. Track.